Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

Description

The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.

Conditions

Interaction

Study Overview

Study Details

Study overview

The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

Condition
Interaction
Intervention / Treatment

-

Contacts and Locations

Spokane

Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington, United States, 99202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 21-64 years old and healthy;
  • * Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer;
  • * Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel;
  • * Have taken hemp or cannabis (in any form) before and tolerated it well;
  • * Willing to abstain from consuming dietary supplements/botanical products and citrus juices for the duration of the study;
  • * Willing to abstain from cannabis/marijuana, hemp, THC- and/or CBD-containing products for several weeks;
  • * Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient day;
  • * Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient day;
  • * Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms), continuing for 1 week after completing the study;
  • * Have the ability to and are willing to comply with the requirements of the study;
  • * Geographically located within a 40-mile radius of Spokane and have the time to participate and;
  • * Can read and speak English
  • * Under the age of 21 or over the age of 64;
  • * Any major illness;
  • * Pregnant or nursing;
  • * History of allergy or intolerance to cannabis or clopidogrel;
  • * Taking concomitant medications, both prescription and non-prescription (including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel;
  • * Never taken cannabis (in any form) before;
  • * Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or the quality of the data;
  • * Currently using or have recently used drugs or other illicit substances for recreational purposes;
  • * Have used cannabis/marijuana, hemp, THC- and/or CBD-containing products within the last 4 weeks;
  • * Have an out-of-range clinical laboratory value such that the study physician considers participation in the study a health risk, or;
  • * Unable to read and speak English

Ages Eligible for Study

21 Years to 64 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Washington State University,

Study Record Dates

2025-12-31